VIDEO: CAR T-cell therapy eligibility different from transplant in multiple myeloma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Currently, we have FDA approval of CAR T-cell therapy in patients who’ve had four or more prior lines of treatment that include a proteasome inhibitor, an immunomodulatory drug, as well as an anti-CD38 monoclonal antibody. Right now, we have to go by the indication that is currently FDA approved. I have to say that CAR T-cell therapy eligibility is different from transplant. So we can have older, intermediate-fit patients get CAR T-cell therapies who otherwise would have not received a transplant because CAR Ts appear to have a shorter [adverse events] period, and patients recover very quickly from those side effects compared to transplantation.